Ignite Creation Date:
2025-12-25 @ 12:45 AM
Ignite Modification Date:
2026-01-04 @ 5:06 PM
Study NCT ID:
NCT03194867
Status:
COMPLETED
Last Update Posted:
2024-06-14
First Post:
2017-06-19
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
Sponsor:
Sanofi
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-02-21
Start Date Type:
ACTUAL
Primary Completion Date:
2023-04-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-04-05
Completion Date Type:
ACTUAL
First Submit Date:
2017-06-19
First Submit QC Date:
None
Study First Post Date:
2017-06-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2024-04-02
Results First Submit QC Date:
None
Results First Post Date:
2024-06-14
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-21
Last Update Post Date:
2024-06-14
Last Update Post Date Type:
ACTUAL